Understand the source comparison
Eczema Peptides 2026 Update: Clinical Trial Comparison
| Peptide Class | Lead Compound | Mechanism | Phase | Primary Endpoint | Completion Date | Key Findings (2026 Data) ||—|—|—|—|—|—|| Thymosin Beta-4 Derivatives | Tβ4 1-4 topical cream | Filaggrin upregulation, ceramide synthesis | Phase 2 | SCORAD reduction ≥5
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide Class | Lead Compound | Mechanism | Phase | Primary Endpoint | Completion Date | Key Findings (2026 Data) ||—|—|—|—|—|—|| Thymosin Beta-4 Derivatives | Tβ4 1-4 topical cream | Filaggrin upregulation, ceramide synthesis | Phase 2 | SCORAD reduction ≥50% at week 16 | Q4 2026 | Interim: 31-point mean SCORAD drop, TEWL normalized in 68% of participants || KPV Tripeptide | KPV 0.5% cream | NF-κB inhibition, IL-31 suppression | Phase 2 | Non-inferiority to triamcinolone 0.1% | Q1 2027 | Interim: comparable EASI reduction, zero skin atrophy cases || Growth Hormone Secretagogues | CJC-1295/Ipamorelin combination | Treg maturation, barrier repair acceleration | Phase 2 | SCORAD reduction + Treg frequency increase | Q2 2027 | Enrollment complete, interim pending || Alpha-MSH Analogs | Subcutaneous KPV injection | Selective NF-κB p65 inhibition | Phase 1b | Safety and pruritus VAS reduction | Completed April 2026 | 64% IL-31 reduction, pruritus VAS 7.2→2.8 |